Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 105

1.

Platelet Serotonin Signaling in Patients With Cardiovascular Disease and Comorbid Depression.

Williams MS, Ziegelstein RC, McCann UD, Gould NF, Ashvetiya T, Vaidya D.

Psychosom Med. 2019 May;81(4):352-362. doi: 10.1097/PSY.0000000000000689.

PMID:
30855555
2.

Functional Magnetic Resonance Imaging in Abstinent MDMA Users: A Review.

Garg A, Kapoor S, Goel M, Chopra S, Chopra M, Kapoor A, McCann UD, Behera C.

Curr Drug Abuse Rev. 2015;8(1):15-25. Review.

PMID:
25731754
3.

Studies of (±)-3,4-methylenedioxymethamphetamine (MDMA) metabolism and disposition in rats and mice: relationship to neuroprotection and neurotoxicity profile.

Mueller M, Maldonado-Adrian C, Yuan J, McCann UD, Ricaurte GA.

J Pharmacol Exp Ther. 2013 Feb;344(2):479-88. doi: 10.1124/jpet.112.201699. Epub 2012 Dec 3.

4.

Diffusion tensor imaging atlas-based analyses in major depression after mild traumatic brain injury.

Rao V, Mielke M, Xu X, Smith GS, McCann UD, Bergey A, Doshi V, Pham DL, Yousem D, Mori S.

J Neuropsychiatry Clin Neurosci. 2012 Summer;24(3):309-15. doi: 10.1176/appi.neuropsych.11080188.

5.

Single oral doses of (±) 3,4-methylenedioxymethamphetamine ('Ecstasy') produce lasting serotonergic deficits in non-human primates: relationship to plasma drug and metabolite concentrations.

Mueller M, Yuan J, McCann UD, Hatzidimitriou G, Ricaurte GA.

Int J Neuropsychopharmacol. 2013 May;16(4):791-801. doi: 10.1017/S1461145712000582. Epub 2012 Jul 24.

PMID:
22824226
6.

Acute effects of zolpidem extended-release on cognitive performance and sleep in healthy males after repeated nightly use.

Kleykamp BA, Griffiths RR, McCann UD, Smith MT, Mintzer MZ.

Exp Clin Psychopharmacol. 2012 Feb;20(1):28-39. doi: 10.1037/a0025237. Epub 2011 Sep 19.

7.

Altered pain responses in abstinent (±)3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") users.

McCann UD, Edwards RR, Smith MT, Kelley K, Wilson M, Sgambati F, Ricaurte G.

Psychopharmacology (Berl). 2011 Oct;217(4):475-84. doi: 10.1007/s00213-011-2303-7. Epub 2011 May 21.

PMID:
21603895
8.

Metabolism and disposition of 3,4-methylenedioxymethamphetamine ("ecstasy") in baboons after oral administration: comparison with humans reveals marked differences.

Mueller M, Goodwin AK, Ator NA, McCann UD, Ricaurte GA.

J Pharmacol Exp Ther. 2011 Jul;338(1):310-7. doi: 10.1124/jpet.111.180612. Epub 2011 Apr 14.

9.
10.

Sleep disturbance and the effects of extended-release zolpidem during cannabis withdrawal.

Vandrey R, Smith MT, McCann UD, Budney AJ, Curran EM.

Drug Alcohol Depend. 2011 Aug 1;117(1):38-44. doi: 10.1016/j.drugalcdep.2011.01.003. Epub 2011 Feb 5.

11.

Peritraumatic heart rate and posttraumatic stress disorder in patients with severe burns.

Gould NF, McKibben JB, Hall R, Corry NH, Amoyal NA, Mason ST, McCann UD, Fauerbach JA.

J Clin Psychiatry. 2011 Apr;72(4):539-47. doi: 10.4088/JCP.09m05405blu. Epub 2010 Oct 19.

PMID:
21034691
12.

Dopamine is not essential for the development of methamphetamine-induced neurotoxicity.

Yuan J, Darvas M, Sotak B, Hatzidimitriou G, McCann UD, Palmiter RD, Ricaurte GA.

J Neurochem. 2010 Aug;114(4):1135-42. doi: 10.1111/j.1471-4159.2010.06839.x. Epub 2010 Jun 1.

13.

Sleep apnea in young abstinent recreational MDMA ("ecstasy") consumers.

McCann UD, Sgambati FP, Schwartz AR, Ricaurte GA.

Neurology. 2009 Dec 8;73(23):2011-7. doi: 10.1212/WNL.0b013e3181c51a62. Epub 2009 Dec 2.

14.

Traumatic burn injury: neuropsychiatric perspectives on risk, outcomes and treatment.

Fauerbach JA, McCann UD.

Int Rev Psychiatry. 2009 Dec;21(6):501-4. doi: 10.3109/09540260903340832. No abstract available.

PMID:
19919202
15.

Sleep deprivation differentially impairs cognitive performance in abstinent methylenedioxymethamphetamine ("Ecstasy") users.

McCann UD, Wilson MJ, Sgambati FP, Ricaurte GA.

J Neurosci. 2009 Nov 4;29(44):14050-6. doi: 10.1523/JNEUROSCI.4654-09.2009.

16.

Further studies on the role of metabolites in (+/-)-3,4-methylenedioxymethamphetamine-induced serotonergic neurotoxicity.

Mueller M, Yuan J, Felim A, Neudörffer A, Peters FT, Maurer HH, McCann UD, Largeron M, Ricaurte GA.

Drug Metab Dispos. 2009 Oct;37(10):2079-86. doi: 10.1124/dmd.109.028340. Epub 2009 Jul 23.

17.

Direct comparison of (+/-) 3,4-methylenedioxymethamphetamine ("ecstasy") disposition and metabolism in squirrel monkeys and humans.

Mueller M, Kolbrich EA, Peters FT, Maurer HH, McCann UD, Huestis MA, Ricaurte GA.

Ther Drug Monit. 2009 Jun;31(3):367-73. doi: 10.1097/FTD.0b013e3181a4f6c2.

18.

Positron emission tomographic studies of brain dopamine and serotonin transporters in abstinent (+/-)3,4-methylenedioxymethamphetamine ("ecstasy") users: relationship to cognitive performance.

McCann UD, Szabo Z, Vranesic M, Palermo M, Mathews WB, Ravert HT, Dannals RF, Ricaurte GA.

Psychopharmacology (Berl). 2008 Oct;200(3):439-50. doi: 10.1007/s00213-008-1218-4. Epub 2008 Jul 27.

19.

Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later.

Griffiths R, Richards W, Johnson M, McCann U, Jesse R.

J Psychopharmacol. 2008 Aug;22(6):621-32. doi: 10.1177/0269881108094300. Epub 2008 Jul 1.

20.

Nonlinear pharmacokinetics of (+/-)3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") and its major metabolites in squirrel monkeys at plasma concentrations of MDMA that develop after typical psychoactive doses.

Mueller M, Peters FT, Maurer HH, McCann UD, Ricaurte GA.

J Pharmacol Exp Ther. 2008 Oct;327(1):38-44. doi: 10.1124/jpet.108.141366. Epub 2008 Jun 30.

PMID:
18591215
21.

Persistent cognitive and dopamine transporter deficits in abstinent methamphetamine users.

McCann UD, Kuwabara H, Kumar A, Palermo M, Abbey R, Brasic J, Ye W, Alexander M, Dannals RF, Wong DF, Ricaurte GA.

Synapse. 2008 Feb;62(2):91-100.

PMID:
17992686
22.

Effects of (+/-) 3,4-methylenedioxymethamphetamine (MDMA) on sleep and circadian rhythms.

McCann UD, Ricaurte GA.

ScientificWorldJournal. 2007 Nov 2;7:231-8. Review.

23.

The effects of sleep deprivation on pain inhibition and spontaneous pain in women.

Smith MT, Edwards RR, McCann UD, Haythornthwaite JA.

Sleep. 2007 Apr;30(4):494-505.

PMID:
17520794
24.

Performance characteristics of depression screening instruments in survivors of acute myocardial infarction: review of the evidence.

Thombs BD, Magyar-Russell G, Bass EB, Stewart KJ, Tsilidis KK, Bush DE, Fauerbach JA, McCann UD, Ziegelstein RC.

Psychosomatics. 2007 May-Jun;48(3):185-94. Review.

PMID:
17478586
25.

Quantitative positron emission tomography studies of the serotonin transporter in humans previously treated with the appetite suppressants fenfluramine or dexfenfluramine.

McCann UD, Szabo Z, Vranesic M, Seckin E, Wand G, Duval A, Dannals RF, Ricaurte GA.

Mol Imaging Biol. 2007 May-Jun;9(3):151-7.

PMID:
17473958
26.

Symptoms of depression predict change in physical health after burn injury.

Thombs BD, Bresnick MG, Magyar-Russell G, Lawrence JW, McCann UD, Fauerbach JA.

Burns. 2007 May;33(3):292-8.

PMID:
17382189
27.

The effect of catecholamine depletion by alpha-methyl-para-tyrosine on measures of cognitive performance and sleep in abstinent MDMA users.

McCann UD, Peterson SC, Ricaurte GA.

Neuropsychopharmacology. 2007 Aug;32(8):1695-706. Epub 2007 Jan 3.

28.

Plasma drug concentrations and physiological measures in 'dance party' participants.

Irvine RJ, Keane M, Felgate P, McCann UD, Callaghan PD, White JM.

Neuropsychopharmacology. 2006 Feb;31(2):424-30.

29.

Individual variation in rapid eye movement sleep is associated with pain perception in healthy women: preliminary data.

Smith MT, Edwards RR, Stonerock GL, McCann UD.

Sleep. 2005 Jul;28(7):809-12.

PMID:
16124658
30.

Amphetamine treatment similar to that used in the treatment of adult attention-deficit/hyperactivity disorder damages dopaminergic nerve endings in the striatum of adult nonhuman primates.

Ricaurte GA, Mechan AO, Yuan J, Hatzidimitriou G, Xie T, Mayne AH, McCann UD.

J Pharmacol Exp Ther. 2005 Oct;315(1):91-8. Epub 2005 Jul 13.

PMID:
16014752
31.

Depression following acute myocardial infarction: a prospective relationship with ongoing health and function.

Fauerbach JA, Bush DE, Thombs BD, McCann UD, Fogel J, Ziegelstein RC.

Psychosomatics. 2005 Jul-Aug;46(4):355-61.

PMID:
16000679
32.

Pharmacokinetic profile of single and repeated oral doses of MDMA in squirrel monkeys: relationship to lasting effects on brain serotonin neurons.

Mechan A, Yuan J, Hatzidimitriou G, Irvine RJ, McCann UD, Ricaurte GA.

Neuropsychopharmacology. 2006 Feb;31(2):339-50.

33.

Post-myocardial infarction depression.

Bush DE, Ziegelstein RC, Patel UV, Thombs BD, Ford DE, Fauerbach JA, McCann UD, Stewart KJ, Tsilidis KK, Patel AL, Feuerstein CJ, Bass EB.

Evid Rep Technol Assess (Summ). 2005 May;(123):1-8. Review. No abstract available.

34.

Recognition and management of complications of new recreational drug use.

Ricaurte GA, McCann UD.

Lancet. 2005 Jun 18-24;365(9477):2137-45. Review.

PMID:
15964451
35.

Quantitative PET studies of the serotonin transporter in MDMA users and controls using [11C]McN5652 and [11C]DASB.

McCann UD, Szabo Z, Seckin E, Rosenblatt P, Mathews WB, Ravert HT, Dannals RF, Ricaurte GA.

Neuropsychopharmacology. 2005 Sep;30(9):1741-50.

36.

Identification and characterization of metallothionein-1 and -2 gene expression in the context of (+/-)3,4-methylenedioxymethamphetamine-induced toxicity to brain dopaminergic neurons.

Xie T, Tong L, McCann UD, Yuan J, Becker KG, Mechan AO, Cheadle C, Donovan DM, Ricaurte GA.

J Neurosci. 2004 Aug 11;24(32):7043-50.

37.
38.

Amphetamine neurotoxicity: accomplishments and remaining challenges.

McCann UD, Ricaurte GA.

Neurosci Biobehav Rev. 2004 Jan;27(8):821-6. Review.

PMID:
15019431
39.

Retraction.

Ricaurte GA, Yuan J, Hatzidimitriou G, Cord BJ, McCann UD.

Science. 2003 Sep 12;301(5639):1479. No abstract available.

PMID:
12970544
40.

Response to O'Shea and Colado: the MDMA neurotoxicity profile might provide clues to mechanisms.

Ricaurte GA, Yuan J, Hatzidimitriou G, Cord BJ, McCann UD.

Trends Pharmacol Sci. 2003 Jun;24(6):275. No abstract available.

PMID:
12823952
41.

Pentagastrin-induced sleep panic attacks: panic in the absence of elevated baseline arousal.

Geraci M, Anderson TS, Slate-Cothren S, Post RM, McCann UD.

Biol Psychiatry. 2002 Dec 15;52(12):1183-9.

PMID:
12488064
43.

Effect of glucoprivation on serotonin neurotoxicity induced by substituted amphetamines.

Yuan J, Cord BJ, McCann UD, Callahan BT, Ricaurte GA.

J Pharmacol Exp Ther. 2002 Nov;303(2):831-9.

PMID:
12388670
44.
45.

Use of MDMA and other illicit drugs by young adult males in northern Spain. A five-year study.

Bobes J, Sáiz PA, González MP, Bascarán MT, Bousoño M, Ricaurte GA, McCann UD.

Eur Addict Res. 2002 Jun;8(3):147-54.

PMID:
12065965
46.

Comparison of (+)-(11)C-McN5652 and (11)C-DASB as serotonin transporter radioligands under various experimental conditions.

Szabo Z, McCann UD, Wilson AA, Scheffel U, Owonikoko T, Mathews WB, Ravert HT, Hilton J, Dannals RF, Ricaurte GA.

J Nucl Med. 2002 May;43(5):678-92. Erratum in: J Nucl Med 2002 Jun;43(6):744.

47.

Effect of depleting vesicular and cytoplasmic dopamine on methylenedioxymethamphetamine neurotoxicity.

Yuan J, Cord BJ, McCann UD, Callahan BT, Ricaurte GA.

J Neurochem. 2002 Mar;80(6):960-9.

48.
49.

Effects of fenfluramine, m-CPP and triazolam on repeated-acquisition in squirrel monkeys before and after neurotoxic MDMA administration.

Winsauer PJ, McCann UD, Yuan J, Delatte MS, Stevenson MW, Ricaurte GA, Moerschbaecher JM.

Psychopharmacology (Berl). 2002 Feb;159(4):388-96. Epub 2001 Nov 23.

PMID:
11823891
50.

Changes in gene expression linked to methamphetamine-induced dopaminergic neurotoxicity.

Xie T, Tong L, Barrett T, Yuan J, Hatzidimitriou G, McCann UD, Becker KG, Donovan DM, Ricaurte GA.

J Neurosci. 2002 Jan 1;22(1):274-83.

Supplemental Content

Loading ...
Support Center